]>
IRCT20200404046937N4 IRCT 2020-08-06 Ahvaz University of Medical Sciences Evaluating the effect of Ivermectin on covid 19 patients Evaluating the efficacy and safety of Ivermectin in the treatment of COVID-19 patients: A double-blind randomized controlled trial, phase II 2020-07-30 anticipated 60 Complete https://irct.ir/trial/49935 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into two Therapeutic groups by random method and used 6 blocks method. Individuals are the randomization unit and randomization tools are statistical software, make a random sequence is by using statistical software allocation concealment is by assigning unique codes, Blinding description: Double blind: Supervisor and the participants are blind to the prescription drug of the target group and the control group.The drug in both groups is exactly the same in pill form and is in exactly the same packages. The packages are distinguished only by mentioning the number and the list of numbers will be at the disposal of the statistical consultant and then the data will be analyzed. 2 COVID 19. Intervention 1: Intervention group: Patients in the itervetion group will receive the drug of this study after treatment with routine medications of the disease, which is 14 mg ivermectin tablet, so that the patient will receive one ivermectin tablet every 12 hours for 3 days and then at the time of discharge, Patient symptoms and laboratory data and CT scans will be reviewed. Intervention 2: Control group: Patients in the control group will receive placebo after treatment with routine medications, which is quite similar to ivermectin, in that the patient will receive one placebo pill every 12 hours for 3 days, and then at the time of discharge, Patient symptoms and laboratory data and CT scans will be reviewed.d. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public Mehran Varnasseri
Razi hospital, Felestin Ave, Amanieh Ave
Ahvaz Iran (Islamic Republic of) 6196514941 +98 61 3333 7446 drvarnasei.m@gmail.com Ahvaz University of Medical Sciences scientific Mehran Varnasseri
Razi hospital, Felestin Ave, Amanieh ave
Ahvaz Iran (Islamic Republic of) 6196514941 +98 61 3333 7446 drvarnaseri.m@gmail.com Ahvaz University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Age ≥18 years Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19 Hospitalized Satisfaction to participate in the study Acceptance of non-participation in another study before the 28th day of the study 18 years no limit Both Patients with a history of allergic reaction to Ivermectin Renal dysfunction Liver dysfunction Pregnancy or deciding to get pregnant or breastfeeding U07.1 Corona virus infection, unspecified Treatment - Drugs Placebo Intervention group: Patients in the itervetion group will receive the drug of this study after treatment with routine medications of the disease, which is 14 mg ivermectin tablet, so that the patient will receive one ivermectin tablet every 12 hours for 3 days and then at the time of discharge, Patient symptoms and laboratory data and CT scans will be reviewed. Control group: Patients in the control group will receive placebo after treatment with routine medications, which is quite similar to ivermectin, in that the patient will receive one placebo pill every 12 hours for 3 days, and then at the time of discharge, Patient symptoms and laboratory data and CT scans will be reviewed.d. Viral diagnostic test. Timepoint: The first day of the study. Method of measurement: Polymerase chain reaction. Duration of hospitalization. Timepoint: Time of dyscharge. Method of measurement: Patient file. Fever. Timepoint: Daily. Method of measurement: Thermometer. Respiratory rate. Timepoint: Daily. Method of measurement: Patient file. Dyspnea. Timepoint: Daily. Method of measurement: Patients interview and patient file. Cough. Timepoint: Daily. Method of measurement: Patients interview and patient file. Cell blood count. Timepoint: The first day of the study and the end of the study. Method of measurement: Lab test. C_reactive protein. Timepoint: The first day of the study and the end of the study. Method of measurement: Lab test. CT scan. Timepoint: The first day of the study and the end of the study. Method of measurement: CT scan set. Ahvaz University of Medical Sciences Approved 2020-06-26 Ethics committee of Ahvaz University of Medical Sciences Ethics committee, main building, Ahvaz jundishapur university of medical science, Golestan Ahvaz Khouzestan Iran (Islamic Republic of)